Christine Anderson
Family · Folsom, CANPI 1356764351
Payments from drug & device makers
Across 443 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- GSK$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$651
- Amgen$611
- Boehringer Ingelheim$470
- plus $3K from 28 others
What the payments were for
- Consulting fees$1,45012%
- Food & beverage$10,46086%
- Education$1952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 118 | $4,504 |
| GSK | 71 | $1,421 |
| Sanofi | 58 | $1,402 |
| Regeneron Healthcare Solutions, Inc. | 23 | $651 |
| Amgen | 33 | $611 |
| Boehringer Ingelheim | 19 | $470 |
| Genentech USA, Inc. | 11 | $330 |
| Kaleo, Inc. | 13 | $328 |
| CSL Behring | 13 | $325 |
| Alk-abello, Inc | 22 | $323 |
| Novartis | 10 | $232 |
| Ionis Pharmaceuticals, Inc. | 4 | $219 |
| Sanofi-aventis U.S. LLC | 2 | $145 |
| Pharming Healthcare, Inc. | 2 | $140 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $116 |
| Optinose US, Inc. | 4 | $93 |
| Teva Pharmaceuticals USA, Inc. | 4 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Hikma Pharmaceuticals USA | 3 | $68 |
| Pulmonx Corporation | 1 | $59 |
| Mylan Specialty L.p. | 3 | $57 |
| Inspire Medical Systems, Inc. | 1 | $49 |
| Merck | 2 | $48 |
| Pfizer | 3 | $44 |
| Grifols USA, LLC | 3 | $43 |
| Lilly USA, LLC | 2 | $38 |
| LEO Pharma Inc. | 2 | $37 |
| Digestive Care, Inc. | 1 | $35 |
| Organon | 2 | $30 |
| Incyte Corporation | 1 | $29 |
| Phadia US Inc. | 1 | $22 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| Octapharma USA, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,104 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $102,179 |
| Spiriva RespimatTiotropium Bromide | 91 | $57,637 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $42,326 |
| SymbicortBudesonide/Formoterol Fumarate | 102 | $37,946 |
| Advair HfaFluticasone Propion/Salmeterol | 45 | $16,931 |
| DuleraMometasone/Formoterol | 36 | $14,750 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $14,547 |
| Arnuity ElliptaFluticasone Furoate | 32 | $11,453 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $10,845 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $10,267 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $8,988 |
| Wixela InhubFluticasone Propion/Salmeterol | 42 | $8,658 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,416 |
| Epinephrine | 30 | $6,425 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 190 | $6,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $1,421 | $142,160227 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $4,504 | $89,259180 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $470 | $72,183109 claims |
| MerckDulera | $48 | $14,75036 claims |
| Hikma Pharmaceuticals USAEpinephrine | $68 | $6,42530 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $91 | $5,59111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Folsom
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.